AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ACDC Metals Ltd

0.041

+0.000

Volume:- -

Turnover:- -

Market Cap:3.00M

PE:-7.31

High:0.041

Open:0.041

Low:0.041

Close:0.041

Loading ...

Overview Company News Filings

Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation

MT Newswires Live

Otsuka's Taiho to Buy Swiss ADC Developer Araris Biotech

MT Newswires Live

CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug

MT Newswires Live

Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%

MT Newswires Live

Coles share price lifts off on dividend boost

Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug

MT Newswires Live

Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility

MT Newswires Live

Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences

MT Newswires Live

Agree Realty Expects to Invest Up to $1.3 Billion in 2025

MT Newswires Live

Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3

MT Newswires Live

Is the Coles share price a buy amid its 2025 outlook?

Trump Media saw the largest increase in short interest in October

BRIEF-Coles Update On Supply Chain Modernisation

Coles share price climbs on Q1 update and $880m investment news

Agree Realty Prices Stock Offering at $74 Per Share

MT Newswires Live

Agree Realty Launches Common Stock Offering; Shares Fall After Hours

MT Newswires Live

Perseus Proteomics, UBE Partner on Antibody-Drug Conjugate Research

MT Newswires Live

CStone Pharmaceuticals Gets Patent Publish for Internally Developed Cancer Drug; Shares Down 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ADC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.041,"timestamp":1744870320000,"preClose":0.041,"halted":0,"volume":0,"delay":0,"nameEN":"ACDC Metals Ltd","floatShares":39337511,"shares":73275130,"eps":-0.005605,"marketStatus":"Market Closed","change":0,"latestTime":"04-17 16:12:00 AEST","open":0.041,"high":0.041,"low":0.041,"amount":0,"amplitude":0,"askPrice":0.045,"askSize":43500,"bidPrice":0.041,"bidSize":153246,"shortable":3,"etf":0,"ttmEps":-0.005605,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":7,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.041,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":39337511,"roa":"-3.02%","roe":"-3.81%","lyrEps":-0.006941,"shares":73275130,"dividePrice":0,"high":0.041,"amplitude":0,"preClose":0.041,"low":0.041,"week52Low":0.041,"pbRate":"0.29","psRate":"-124.62","week52High":0.095,"institutionHeld":0,"latestPrice":0.041,"committee":0.557805,"eps":-0.005605,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.005605,"open":0.041,"prevYearClose":0.055,"prevWeekClose":0.042,"prevMonthClose":0.045,"prevQuarterClose":0.045,"fiveDayClose":0.047,"twentyDayClose":0.041,"sixtyDayClose":0.053},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522134338","title":"Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2522134338","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522134338?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:44","pubTimestamp":1743061459,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology  said its novel CD228-directed antibody-drug conjugate , BA1302, received Orphan Drug Designation  from the Food and Drug Administration  for the treatment of squamous non-small cell lung cancer  and pancreatic cancer, according to a Wednesday filing with the Hong Kong bourse.BA1302 targets CD228, a protein overexpressed in multiple tumors, to inhibit cancer cell migration and proliferation while minimizing off-target toxicity.The biopharmaceutical company's shares were up 2% in recent trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ODD","BK4183","06955","ADC","BK4231","BK1161","ADC.AU","BK7095","BK4080"],"gpt_icon":0},{"id":"2520635265","title":"Otsuka's Taiho to Buy Swiss ADC Developer Araris Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2520635265","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520635265?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:06","pubTimestamp":1742256371,"startTime":"0","endTime":"0","summary":"Otsuka Holdings  said its unit, Taiho Pharmaceutical, will acquire Swiss biotech firm Araris Biotech for up to $1.14 billion to strengthen its antibody-drug conjugate  pipeline, according to a Monday filing on the Tokyo Stock Exchange.Taiho will pay $400 million upfront and potential additional milestone payments of up to $740 million. The deal is expected to close in the first half of 2025.Price : $7712.00, Change: $+94, Percent Change: +1.23%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4231","ADC","ADC.AU","BK4080","BK7095"],"gpt_icon":0},{"id":"2517185242","title":"CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185242?lang=en_us&edition=fundamental","pubTime":"2025-03-06 14:46","pubTimestamp":1741243589,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  submitted the Phase I-B trial application in Australia for its large B-cell lymphoma  drug, according to a Thursday filing with the Hong Kong bourse.CS5001 is an ROR1-targeting antibody-drug conjugate  that works with first-line standard-of-care  to diffuse large B-cell lymphoma , the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK4080","BK1161","XJO.AU","XAO.AU","XKO.AU","BK1574","ADC","ADC.AU","BK4231","02616"],"gpt_icon":0},{"id":"2516576704","title":"Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516576704","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516576704?lang=en_us&edition=fundamental","pubTime":"2025-03-03 12:21","pubTimestamp":1740975711,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  said the first patient was enrolled in its phase three trial for BL-B01D1, according to a Monday filing with the Shanghai bourse.BL-B01D1 is a dual antibody-drug conjugate  combined with Osimertinib for treating EGFR-mutated advanced non-small cell lung cancer.Shares of the pharmaceutical company were down 4% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK7095","ADC.AU","BK4231","688506","BK0239","ADC"],"gpt_icon":0},{"id":"2514789050","title":"Coles share price lifts off on dividend boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2514789050","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514789050?lang=en_us&edition=fundamental","pubTime":"2025-02-27 07:33","pubTimestamp":1740612790,"startTime":"0","endTime":"0","summary":"Commenting on the results boosting the Coles share price today, CEO Leah Weckert said:  We have had a strong focus on value, fresh quality and availability which has supported volume-led growth in Supermarkets during the half…Looking at what could impact the Coles share price in the months ahead, the company reported that in the first seven weeks of the third quarter , its Supermarkets sales revenue grew by 3.4% compared to the same period last year. Coles Liquor segment posted sales revenue growth of 3.8%. \"Our focus in the second half remains on providing a compelling customer value proposition, making further progress on improving our fresh offer and continuing to tailor our ranges to make","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/27/coles-share-price-lifts-off-on-dividend-boost/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7095","ADC","COL.AU","BK7082","BK7501","BK7040","BK4231","BK4080","ADC.AU","XJO.AU"],"gpt_icon":0},{"id":"2505627362","title":"Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505627362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505627362?lang=en_us&edition=fundamental","pubTime":"2025-01-21 10:39","pubTimestamp":1737427147,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.SKB445, a new antibody-drug conjugate  drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.The pharmaceutical company's shares were up by 1% in recent trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4231","ADC","BK7095","BK4080","BK1161","ADC.AU","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2504972351","title":"Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2504972351","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504972351?lang=en_us&edition=fundamental","pubTime":"2025-01-17 10:18","pubTimestamp":1737080302,"startTime":"0","endTime":"0","summary":"Samsung Biologics  entered the antibody-drug conjugate  sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.The company has deepened its collaboration with LigaChem Biosciences , signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","ADC","ADC.AU","BK4231","BK4080"],"gpt_icon":0},{"id":"2502072716","title":"Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2502072716","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502072716?lang=en_us&edition=fundamental","pubTime":"2025-01-10 08:57","pubTimestamp":1736470660,"startTime":"0","endTime":"0","summary":"Samsung Biologics  extended its partnership with LigaChem Biosciences to provide antibody-drug conjugate  services at its new ADC facility, the South Korean biotechnology firm said Thursday.The collaboration focuses on ADC programs for solid tumor treatments. Samsung's facility, equipped with a 500-liter reactor, offers end-to-end ADC services from development to conjugation, using its expertise in large-scale antibody manufacturing, it said.Shares of Samsung Biologics rose nearly 1% in recent trade on Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC.AU","BK4231","BK4080","BK7095","ADC"],"gpt_icon":0},{"id":"2501601762","title":"Agree Realty Expects to Invest Up to $1.3 Billion in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501601762","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501601762?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:32","pubTimestamp":1736199169,"startTime":"0","endTime":"0","summary":"Agree Realty  said Monday it expects to invest $1.1 billion to $1.3 billion in 2025.The investments will include capital deployment through the acquisition, development and developer funding platform, the company said.Total real estate investment volume in 2024 was $951 million, the company said.Share of Agree Realty fell 1.8% in recent after-hours activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC.AU","BK4231","BK4080","BK7095","ADC"],"gpt_icon":0},{"id":"2500999346","title":"Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3","url":"https://stock-news.laohu8.com/highlight/detail?id=2500999346","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500999346?lang=en_us&edition=fundamental","pubTime":"2025-01-02 13:10","pubTimestamp":1735794641,"startTime":"0","endTime":"0","summary":"Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.This collaboration aims to bring ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1589","ADC.AU","BK4080","01801","LU1969619763.USD","BK4231","BK1161","BK1583","ADC","LU2328871848.SGD","LU2488822045.USD","BK7095"],"gpt_icon":0},{"id":"2491368303","title":"Is the Coles share price a buy amid its 2025 outlook?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491368303","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491368303?lang=en_us&edition=fundamental","pubTime":"2024-12-13 06:11","pubTimestamp":1734041485,"startTime":"0","endTime":"0","summary":"The Coles Group Ltd  share price has gone through plenty of volatility this year, but it seems to be ending the year on a high, as shown on the chart below. With the company close to its 52-week high, we're going to look at whether the company is an attractive investment with 2025 in mind.  As one of the largest supermarket businesses in Australia, it's benefited from the inflationary period over the last couple of years. However, now that food inflation has significantly reduced, the sector is no longer getting an extra revenue boost. So, will Coles be able to keep growing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/13/is-the-coles-share-price-a-buy-amid-its-2025-outlook/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WOW.AU","ADC.AU","BK4231","COL.AU","BK4080","BK7511","BK7501","BK7040","EBIT","BK7082","ADC","BK7095"],"gpt_icon":0},{"id":"2485114959","title":"Trump Media saw the largest increase in short interest in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2485114959","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485114959?lang=en_us&edition=fundamental","pubTime":"2024-11-20 23:57","pubTimestamp":1732118245,"startTime":"0","endTime":"0","summary":"hyejin kang/iStock via Getty Images Trump Media & Technology (DJT) and Lucid Group (LCID) saw the largest increases in short interest in October, while Expand Energy Corp. (EXE), and Pilgrim’s Pride (","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141852985/image_1141852985.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141852985/image_1141852985.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4312369-trump-media-saw-the-largest-increase-in-short-interest-in-october","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["SWKS","XLP","AMTM","HUM.AU","FOUR","BIRK","EXE","AMKR","APO","ENPH","LINE","ADC.AU","ODFL","OLLI","NTRA","VERX","IWV","SMMT","CELH","PPC","WHR","DOCU","RBC","VRNS","AAL","CRC","HUM","DJT","LCID","AAL.AU","ADC","MC","CORT","GAP.AU","PPC.AU","XLU","GAP","CG","CNX","SFM.AU","ENSG","WEX","SFM","EAT","CART","SIRI","MDGL"],"gpt_icon":1},{"id":"2479304790","title":"BRIEF-Coles Update On Supply Chain Modernisation","url":"https://stock-news.laohu8.com/highlight/detail?id=2479304790","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479304790?lang=en_us&edition=fundamental","pubTime":"2024-10-31 09:10","pubTimestamp":1730337023,"startTime":"0","endTime":"0","summary":"Oct 31  - Coles Group Ltd   :   * UPDATE ON COLES SUPPLY CHAIN MODERNISATION   * INVESTING A$880 MILLION TO DEVELOP A NEW AMBIENT AUTOMATED DISTRIBUTION CENTRE  IN TRUGANINA   * INVESTING A$880 MILLION TO DEVELOP A NEW AMBIENT AUTOMATED DISTRIBUTION CENTRE   * EXPECTS TO RECOGNISE A PROVISION OF AROUND A$35 MILLION BEFORE TAX IN 1H25   * INVESTMENT IN PARTNERSHIP WITH WITRON AUSTRALIAFurther company coverage:    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7082","BK7501","BK7040","COL.AU","ADC.AU","BK7095"],"gpt_icon":0},{"id":"2479931057","title":"Coles share price climbs on Q1 update and $880m investment news","url":"https://stock-news.laohu8.com/highlight/detail?id=2479931057","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479931057?lang=en_us&edition=fundamental","pubTime":"2024-10-31 07:13","pubTimestamp":1730330006,"startTime":"0","endTime":"0","summary":"The Coles Group Ltd  share price is back on form on Thursday. In morning trade, the supermarket giant's shares are up 1% to $17.90. Why is the Coles share price rising?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/31/coles-share-price-climbs-on-q1-update-and-880m-investment-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7040","BK7082","ADC.AU","ADC","BK7095","BK4080","COL.AU","BK4231","BK7501"],"gpt_icon":0},{"id":"2478435671","title":"Agree Realty Prices Stock Offering at $74 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2478435671","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478435671?lang=en_us&edition=fundamental","pubTime":"2024-10-25 15:54","pubTimestamp":1729842848,"startTime":"0","endTime":"0","summary":"Agree Realty (ADC) said late Thursday it priced a public offering of 4.4 million common shares at $74 per share pursuant to certain forward sale agreements.Underwriters have been granted a 30-day opti","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4231","ADC","ADC.AU","BK7095","BK4080"],"gpt_icon":0},{"id":"2478943046","title":"Agree Realty Launches Common Stock Offering; Shares Fall After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2478943046","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478943046?lang=en_us&edition=fundamental","pubTime":"2024-10-25 05:37","pubTimestamp":1729805855,"startTime":"0","endTime":"0","summary":"Agree Realty  said late Thursday it launched a public offering of 4 million common shares.The company expects to grant a 30-day overallotment option to the underwriters to acquire up to 600,000 additional shares.Agree Realty said it expects to use any net proceeds it receives upon the future settlement of certain forward sale agreements it plans to sign in connection with the offering for general corporate purposes.The company's shares were down 2.1% in after-hours activity.Price: 73.45, Change: -1.55, Percent Change: -2.07","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","ADC","BK4231","BK4080","ADC.AU"],"gpt_icon":0},{"id":"2477584196","title":"Perseus Proteomics, UBE Partner on Antibody-Drug Conjugate Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2477584196","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477584196?lang=en_us&edition=fundamental","pubTime":"2024-10-22 08:01","pubTimestamp":1729555283,"startTime":"0","endTime":"0","summary":"Perseus Proteomics  and UBE have entered a collaborative research agreement focused on antibody-drug conjugates , which are used to kill cancer cells, according to its filing on Monday.The partnership will enhance the development of PPMX-T004, an ADC, and explore additional ADCs using external drug discovery sources.Their combined technologies will optimize antibody and drug/linker combinations for effective treatments.Price : $610.00, Change: $+2.0, Percent Change: +0.33%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC.AU","ADC","BK4231","BK7095","BK4080"],"gpt_icon":0},{"id":"2477029036","title":"CStone Pharmaceuticals Gets Patent Publish for Internally Developed Cancer Drug; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477029036","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477029036?lang=en_us&edition=fundamental","pubTime":"2024-10-21 10:11","pubTimestamp":1729476668,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  said a patent was published for its internally developed antibody-drug conjugate  CS5006 on October 10, according to a filing with the Hong Kong bourse.CS5006 is a new type of cancer drug designed to target a protein called integrin β4 , which combines with another protein, integrin α6 , to form a pair called α6β4. Using advanced technology and AI, researchers found that ITGB4 is common in cancers like lung, colon, esophageal, and head and neck cancers. This discovery suggests that targeting ITGB4 may be an effective way to treat these cancers.The pharmaceutical company's shares were down nearly 3% in recent trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02616","BK1161","ADC.AU","BK4231","BK4080","BK7095","ADC","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[]}}